Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial
Primary result · Change in body weightResult — go to the resultEstimated treatment difference −8.7 kg 95% CI −12.0 to −5.5Authors' conclusion
Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.
Study context
- Population
- Adults with T1D and BMI >30 kg/m²22 completed
- Participants
- 24 adults
- Comparison
- Once-weekly SC tirzepatide vs placebo
- Primary endpoint
- Change in body weight
- Follow-up
- 12 weeks
Methodological detailsphase 2, double-blind, placebo-controlled
- Phase 2
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Estimated treatment difference
−8.7 kg
95% CI −12.0 to −5.5
P < 0.0001
Change by group
Tirzepatide
−10.3
mean · 95% CI −12.8–-7.7 · kg
Placebo
−0.7
mean · 95% CI −1.4–2.8 · kg
Tirzepatidevs Placebo
estimated treatment difference −8.7 kg (95% CI −12.0 to −5.5); P < 0.0001
Further findings
Weight loss ≥5% · 12 weeks
Weight loss ≥10% · 12 weeks
Units/day
| Outcome | Tirzepatide | Placebo | Estimate | P value | |
|---|---|---|---|---|---|
| HbA1c | mean difference −0.4 % (95% CI −0.7 to 0.0) | P = 0.05 | |||
| Total daily insulin dose | −24.2 | −0.3 | difference from baseline vs. placebo −35.1 % (95% CI −46.5 to −21.3) | P = 0.0002 | |
| −60−40−20020Difference, % (linear scale) |
Safety
- No significant adverse events in either group
Original publication
Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. Diabetes Care. Published 20 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →